We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.10 | -1.52% | 6.49 | 6.00 | 6.98 | 203,677 | 16:35:20 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.75 | 13.27M |
From Apr 2019 to Apr 2024
TIDMSNG
RNS Number : 9009D
Synairgen plc
12 October 2018
Correction: In the Company's RNS published at 10.29am this morning (RNS number 8911D) the time the admission of the New Ordinary Shares was incorrectly stated as being at 8.00 a.m. on Monday 15 September 2018. The correct time for the admission of the New Ordinary Shares is 8.00 a.m. on Monday 15 October 2018 and this has been corrected in the replacement RNS set out below. All other content remains unchanged.
Synairgen plc
('Synairgen' or the 'Company')
Result of General Meeting
Further to Synairgen's announcement of 25 September 2018, the Company is pleased to announce today the passing of the Resolutions at the General Meeting held earlier today. The Placing and Subscription remain conditional on Admission of the New Ordinary Shares to AIM, which is expected to take place at 8.00 a.m. on Monday 15 October 2018.
With effect from Admission, the Company will have 109,433,442 Ordinary Shares in issue, with no shares held in treasury. Shareholders may use this figure as the denominator by which they are required to notify their interest in, or change to their interest in, the Company under the Disclosure Guidance and Transparency Rules.
Following Admission, the shareholdings of the below Directors of the Company, who participated in the Fundraise, are as follows:
Hot Features
Premium
Director Ordinary Shares Ordinary Shares Ordinary Shares Percentage
held prior subscribed held after of the Enlarged
to the Fundraise for in the the Fundraise Issued Share
Fundraise Capital held
Richard Marsden 154,432 156,250 310,682 0.28%
------------------ ---------------- ---------------- -----------------
Dr Phillip
Monk 183,439 46,875 230,314 0.21%
------------------ ---------------- ---------------- -----------------
John Ward 276,506 62,500 339,006 0.31%
------------------ ---------------- ---------------- -----------------
Capitalised terms in the text of this announcement have the meanings given to them in the Company's circular dated 26 September 2018.
For further enquiries, please contact:
Synairgen plc
Richard Marsden, Chief Executive Officer
John Ward, Finance Director
Tel: + 44 (0) 23 8051 2800
finnCap
Geoff Nash, Max Bullen-Smith (Corporate Finance)
Alice Lane (ECM)
Tel: + 44 (0) 20 7220 0500
Consilium Strategic Communications (Financial Media and Investor
Relations)
Mary-Jane Elliott / Sukaina Virji / Laura Thornton
synairgen@consilium-comms.com
Tel: +44 (0) 20 3709 5701
Notes for Editors
About Synairgen
Synairgen is a respiratory drug discovery and development company founded by University of Southampton Professors Stephen Holgate, Donna Davies and Ratko Djukanovic. The business, focused primarily on asthma and COPD, uses its differentiating human biology BioBank platform and world-renowned international academic KOL network to discover and develop novel therapies for respiratory disease. Leveraging its scientific and clinical facilities at Southampton General Hospital, the Company uses in vitro and ex vivo models to progress opportunities into clinical development. The BioBank of human samples is used in these models to increase confidence in the likelihood of successful drug development.
Synairgen is currently running a two-part Phase II trial evaluating SNG001, the Company's wholly-owned inhaled interferon beta (IFN-beta) therapeutic candidate. The Phase II trial, called SG015, has been designed to assess the safety of SNG001 in COPD patients and its clinical benefit in these patients when they have a cold or flu infection, a major driver of COPD exacerbations.
Core to Synairgen's business strategy is the realisation of value via licensing transactions. In August 2015 the Company entered into a collaboration with Pharmaxis to develop an oral LOXL2 inhibitor to reduce fibrosis in patients with idiopathic pulmonary fibrosis (IPF). In December 2017 the collaboration agreement was amended as Pharmaxis took on full responsibility for the programme, with Synairgen receiving a GBP5 million upfront payment and circa 17% of any future net partnering proceeds from all fibrotic indications.
Synairgen is quoted on AIM (LSE: SNG). For more information about Synairgen, please see www.synairgen.com
The information communicated in this announcement is inside information for the purposes of Article 7 of Regulation 596/2014.
Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Richard Marsden
------------------------------- ------------------------------------
2. Reason for the Notification
---------------------------------------------------------------------
a) Position/status PDMR - CEO
------------------------------- ------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name Synairgen plc
------------------------------- ------------------------------------
b) LEI 213800IMMTOPPDF8HD24
------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
---------------------------------------------------------------------
a) Description of the Ordinary Shares of
Financial instrument, 1 p each
type of instrument
Identification code GB00B0381Z20
------------------------------- ------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
16 pence 156,250
----------
------------------------------- ------------------------------------
d) Aggregated information:
* Aggregated volume N/A, single transaction as per 4c
above
* Price
------------------------------- ------------------------------------
e) Date of the transaction 12 October 2018
------------------------------- ------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
------------------------------- ------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name Dr. Phillip Monk
------------------------------- ------------------------------------
2. Reason for the Notification
---------------------------------------------------------------------
a) Position/status PDMR - Chief Scientific Officer
------------------------------- ------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name Synairgen plc
------------------------------- ------------------------------------
b) LEI 213800IMMTOPPDF8HD24
------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
---------------------------------------------------------------------
a) Description of the Ordinary Shares of
Financial instrument, 1 p each
type of instrument
Identification code GB00B0381Z20
------------------------------- ------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
16 pence 46,875
----------
------------------------------- ------------------------------------
d) Aggregated information:
* Aggregated volume N/A, single transaction as per 4c
above
* Price
------------------------------- ------------------------------------
e) Date of the transaction 12 October 2018
------------------------------- ------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
------------------------------- ------------------------------------
1. Details of the person discharging managerial responsibilities
/ person closely associated
a) Name John Ward
------------------------------- ------------------------------------
2. Reason for the Notification
---------------------------------------------------------------------
a) Position/status PDMR - Finance Director
------------------------------- ------------------------------------
b) Initial notification/Amendment Initial notification
------------------------------- ------------------------------------
3. Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
---------------------------------------------------------------------
a) Name Synairgen plc
------------------------------- ------------------------------------
b) LEI 213800IMMTOPPDF8HD24
------------------------------- ------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place where
transactions have been conducted
---------------------------------------------------------------------
a) Description of the Ordinary Shares of
Financial instrument, 1 p each
type of instrument
Identification code GB00B0381Z20
------------------------------- ------------------------------------
b) Nature of the transaction Purchase of Ordinary Shares
------------------------------- ------------------------------------
c) Price(s) and volume(s) Price(s) Volume(s)
16 pence 62,500
----------
------------------------------- ------------------------------------
d) Aggregated information:
* Aggregated volume N/A, single transaction as per 4c
above
* Price
------------------------------- ------------------------------------
e) Date of the transaction 12 October 2018
------------------------------- ------------------------------------
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
------------------------------- ------------------------------------
This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
END
ROMGGGPUUUPRGUP
(END) Dow Jones Newswires
October 12, 2018 06:05 ET (10:05 GMT)
1 Year Synairgen Chart |
1 Month Synairgen Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
